Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial and Re: CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients

J Natl Cancer Inst. 2012 Aug 22;104(16):1263-4; author reply 1266-8. doi: 10.1093/jnci/djs312. Epub 2012 Jul 31.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antineoplastic Agents, Hormonal / therapeutic use*
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / enzymology*
  • Breast Neoplasms / epidemiology*
  • Breast Neoplasms / prevention & control*
  • Cytochrome P-450 CYP2D6 / genetics*
  • Female
  • Glucuronosyltransferase / genetics*
  • Humans
  • Neoplasm Recurrence, Local / epidemiology*
  • Neoplasm Recurrence, Local / prevention & control*
  • Nitriles / therapeutic use*
  • Polymorphism, Single Nucleotide*
  • Postmenopause*
  • Tamoxifen / therapeutic use*
  • Triazoles / therapeutic use*

Substances

  • Antineoplastic Agents, Hormonal
  • Nitriles
  • Triazoles
  • Tamoxifen
  • Cytochrome P-450 CYP2D6
  • Glucuronosyltransferase